A promising pharmaceutical product can encounter avoidable delays when its regulatory pathway, evidence requirements, manufacturing strategy or documentation gaps are identified too late. Decisions made during development can affect the studies required, the quality evidence generated, the submission plan and the time and resources needed to prepare for regulatory review.
Early regulatory planning helps teams identify these requirements before major development decisions are finalised. It connects the intended markets and regulatory pathway with clinical, nonclinical, chemistry, manufacturing and controls (CMC), quality and safety activities. The aim is not to bypass scientific or regulatory requirements, but to plan for them in a structured and timely way.
Regulatory authorities may also offer opportunities for early interaction. For example, the European Medicines Agency (EMA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) have scientific advice procedures that can help eligible sponsors discuss relevant development questions. The applicable process and scope depend on the authority and product.
What Is Early Regulatory Planning?
Early regulatory planning is the process of defining the likely regulatory pathway, evidence needs, applicable requirements, key risks and submission approach before a product reaches the submission stage.
A structured plan may include:
- Identifying the intended markets and applicable regulatory requirements
- Assessing potential authorisation pathways and product classification
- Defining clinical, nonclinical, CMC and quality evidence needs
- Identifying regulatory, technical and documentation gaps
- Planning relevant interactions with health authorities
- Assigning responsibilities, dependencies, milestones and decision points
Regulatory planning and regulatory submission are related but distinct. Planning defines what needs to be developed, justified and documented; submission preparation assembles and presents the resulting evidence to the relevant authority. Starting early helps teams make informed decisions before significant time and resources have been committed.
Why Start Regulatory Planning Early?
1. Understand requirements before committing resources
Regulatory expectations can differ between markets and according to product type, development stage and proposed route to market. Early assessment helps teams understand the likely requirements for clinical development, nonclinical evidence, CMC, quality, safety and documentation. Where several markets are planned, the strategy should account for relevant jurisdiction-specific differences.
2. Identify evidence gaps
A structured gap assessment can identify missing, incomplete or potentially insufficient evidence before submission preparation begins. Examples may include study design questions, incomplete CMC documentation, limited stability data, unsuitable specifications, analytical method issues or insufficient justification for key development decisions.
3. Reduce avoidable late-stage changes
If requirements are identified late, teams may need to repeat work, generate additional data, revise documents or change development plans. Earlier identification allows these activities to be assessed and prioritised while there is more flexibility in the programme.
Five Areas to Assess Before Committing to a Regulatory Pathway
1. Regulatory pathway and target markets
Clarify the intended markets, product classification, proposed authorisation route and key submission requirements. The pathway should reflect the product, its development stage and the requirements of each relevant jurisdiction.
2. CMC, manufacturing and quality readiness
Assess manufacturing arrangements, product specifications, analytical methods, validation requirements, stability evidence and supporting quality documentation. These elements should develop in step with the product and its proposed regulatory strategy.
3. Evidence gaps and data readiness
Consider whether the available clinical, nonclinical, quality and stability evidence supports the proposed development and regulatory approach. Document outstanding studies, analyses, justifications and decisions, with owners and target dates where possible.
4. Submission planning and document consistency
Establish document ownership, timelines, dependencies and review responsibilities. Review relevant submission components progressively and check that the product information, quality documentation and supporting evidence are consistent.
5. Ongoing regulatory and compliance obligations
Consider relevant manufacturing and quality compliance requirements, pharmacovigilance responsibilities and lifecycle commitments where applicable to the product and proposed route to market. These obligations should be understood alongside the initial authorisation plan.
How Early Planning Can Improve Submission Readiness
1. Define the regulatory pathway
The strategy should consider product type, intended indication, target markets, development stage and applicable requirements. It should translate these considerations into a development direction, key milestones and decision points.
2. Align evidence with regulatory expectations
Clinical, nonclinical, CMC and quality activities should not operate as isolated workstreams. Together, they generate and support the evidence needed to assess the product against the applicable requirements and development objectives. For example, clinical endpoints should fit the development objectives, while CMC activities should progressively establish product quality and manufacturing controls.
3. Plan appropriate regulatory interactions
Where appropriate, scientific advice or other authority interactions can help sponsors discuss specific development questions before major decisions are finalised. The availability, process and scope of these interactions vary by authority and product.
4. Build submission readiness progressively
Submission readiness should be developed throughout the programme rather than treated as a final-stage exercise. Reviewing reports, data summaries, supporting documentation and relevant CTD/eCTD components as they develop can help identify inconsistencies and outstanding work earlier.
Early regulatory planning can reduce avoidable development and submission risks, but it does not guarantee regulatory approval or a specific review timeline.
Aligning Clinical, Nonclinical and CMC Strategy
An effective regulatory strategy connects the major development workstreams and makes clear how each contributes to the overall evidence package.
1.Clinical development
Consider the intended patient population, study design, endpoints and statistical approach so that the planned evidence addresses the development objectives and applicable regulatory expectations.
2. Nonclinical development
Pharmacology and toxicology programmes should be appropriately aligned with the proposed clinical programme and relevant regulatory requirements.
3. CMC and quality
CMC planning includes manufacturing processes, product quality, stability, specifications and control strategies. ICH Q8 on pharmaceutical development, ICH Q9 on quality risk management and ICH Q10 on the pharmaceutical quality system provide important frameworks for relevant aspects of development and quality management.
The central principle is integration: development decisions should collectively support the product’s quality, safety and efficacy profile.
How Sciom Supports Early Pharmaceutical Regulatory Planning
Turning regulatory requirements into a practical action plan
Early regulatory planning is most effective when regulatory strategy, pharmaceutical quality, manufacturing and submission requirements are considered together.
Sciom supports pharmaceutical companies with regulatory pathway assessment, regulatory gap analysis, submission planning and regulatory compliance support. Its approach focuses on translating requirements into practical actions, helping clients understand what needs to be addressed, which activities should be prioritised and how outstanding requirements may affect development or market-entry plans.
By considering regulatory and quality requirements early, companies can make more informed decisions, identify potential obstacles before submission and improve overall regulatory readiness.
Planning a pharmaceutical product’s route to market? Contact Sciom to discuss your product, target markets and regulatory requirements, and identify the next steps towards a structured regulatory strategy.
Conclusion
Regulatory planning should begin well before a pharmaceutical product reaches the submission stage. Identifying requirements, assessing evidence gaps, aligning clinical, nonclinical, CMC and quality activities, and considering appropriate authority interactions can help companies reduce avoidable risks and improve submission readiness.
A proactive approach creates a clearer connection between development decisions and regulatory requirements. Effective regulatory planning is not simply about preparing a submission; it is about building a considered development pathway from the beginning.